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Figure 1. Proteins are present on plant leaf surfaces. 
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a. Water Control 
Figure 2. Proteins in T1 1068 LWW ' 'bit 1’. tabacina spore germination and leaf 
infection. 
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M A S 
AACACAATTTCTTACAGCAATAACTATCACATATAACAATAACTGCC ATG GCT TCA 56 
A K I F L I F L L A A L I A T 
GCA AAA ATT TTC TTG A'I‘T TTC CTT TTG GCT GS? TTA ATC GCA ACC 101 
aa 
P A A F A I L V P T L V S T H 
CCC GCT GCA TTT GCC ATA CTT GT'I‘ CCA ACA CTT GTT TCA ACA CAT 146 
I S G L V F C S V N G N L D V 
ATA AGT GGG CTT GTA TTT TGC AGC GTT AAC GGC AAT TTA GAT GTC 191 
aa-Tl 
I N G L S P Q V F P N A S V Q 
ATC AAC GGA CTC AGT CCC CAA GTT TTT CCT AAT GCA TCA GTG CAA 236 
aa-T2 
L R C G A T N v I s S T I T N 
TTG CGG TGT GGA GCA ACA AAT GTG ATA TCA AGT ACA ATA ACA AAT 281 
G S G A F S L A V N T F P L L 
GGA TCG GGA GCA TTT TCC TTG GCG GTG AAT ACT TTC CCA CTG CTA 326 
aa-T3 
N C N L V V A T P L S T C N A 
AAC TGC AAT TTA GTG GTT GCA ACT CCA CTA TCA ACA TGT AAC GCG 371 
T L Q S V G R L A S S L R L V 
ACC TTA CAA TCG GTT GGG CGT TTG GCG TCA TCC TTG éKaGAPJCTT GTA 416 
N I T L G S G T G L I R V G L 
AAT ATC ACT CTT GGC AGT GGC ACC TG4GT CTT ATT AGA GTC GGT TTA 461 
aa 
A P T G F I L N L N I N * (SEQ ID NO:18) 
GCT CCT ACT GGT TTT ATA CTT AAT CTT AAC ATC AAT E TATTGAAC 50B 
GAGCTAGCCTGCTGGTTCTTAATTAGTACTACTACTATGCATCAGCTAGTTAACTTTCTT 568 
GGCCAGCTGCTTACTGCAAGAATAAGGACTGTTGTTTCCACTAGTGAATAAAGTGCAAAT 628 
CATATTTGCAAGTCT ' ‘ ‘ (SEQ ID NO:17) 666 
Figure 3. Nucleotide and predicted amino acid sequence of TI 1068 Phylloplanin 
cDNA. 
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MBP+Pr0tK 
'bi P. tabacina spore germination. Figure 4. E. Cali-expressed TI 1068 phylloplanin 
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nly in short glandular Figure 5. The phylloplanin promo r directs protein axpression 0 
trichomes (SGTs). 
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—1157 cccattccac tatgaacttc ccggaattca attctgacta tgcgtacaag tcataatgaa 
—1097 gctgcacata gccttcatat cgctaaacga cgtgctaggt ctcaaaacga cctgtcgggg 
—1037 tcgttacatt agaggtgatt aacttcgtgt atacttgtgc aagtgttcta taacaatttc 
—977 
—917 
—857 
—797 
—737 
—677 
—617 
—557 
~49? 
—437 
—377 
—3l7 
—257 
—l97 
—137 
aggccaacct 
gtacatgata 
gcctaggaca 
gtaagaatat 
cactggcact 
aattattcac 
gattgaatgg 
ggcaacacta 
tatgcaaatg 
attaaataaa 
tacatgacca 
tatttttctc 
aatgtttaga 
agttatagtc 
ttgaaatttc 
agtaagagta 
taactcacac 
tcacaagata 
ttcacacttt 
gccaaaaagc 
ttagtattct 
attggtccac 
attgcactat 
ataattttat 
atataactaa 
aacacaattt 
caaagtgact 
agtcaaggat 
agggtgacca 
aattagttca 
gaaatagtga 
aaggtaggca 
tgaaaaatca 
ttagggcact 
cctctacact 
ttacattagg 
tctattatta 
caacaaagta 
ttaaaacaat 
gaaaaaaaat 
gtttatcaaa 
tatgaattac 
gggcttcttt 
ccagcatctc 
ttcaaatata 
atggcacata 
cgctactaga 
atccttacta 
aagatcactc 
gtagtgaatt 
ttcccccctt 
cagagtaatt 
ttagttctag 
agatgtacat 
ttaaagttca 
tactttcaaa 
tatgttgata 
tgattattga 
atatagcaat 
cacgtaatag 
acaaacgatc 
caattaccaa 
tcacggttga 
caccaacatt 
tttgttagtt 
ctaggtcctg 
attaaatttt 
ccttctgggt 
ggatataaat 
ctcctaagat 
agaatttgtc 
aaatactttt 
agtttgtagc 
acacaagtgg 
cattataagc 
accacgaaat 
taacaacaat 
gttgtaacgt 
tcaagagaat 
atctaaagtt 
cacgtaacta 
tatttgacta 
acttcatacc 
acctatgaaa 
atcgggttat 
aaacgtaaat 
caaagtaact 
aattgtatgt 
gttagcgtat 
cactttcaca 
—77 acagatagat taggggtttt aaaatttcaa. ccaatgatat ttactataaa ttgatcatgc 
—17 acaaacctta attgagcgac acaatttctt acagcaataa ctatcacata taacaataac 
M A S A K I F L I E‘ L L (SEQ ID {10:49) 
+44 tgccatggct tcagcaaaaa ttttcttgat tttccttttg gctgcatta (SEQ ID NO:50) 
A A L 
FIGURE 9 
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UTILITY OF PHYLLOPLANINS AS 
ANTIBIOTICS, SELECTIVE FUNGICIDES 
AND FOR ENHANCING MICROBIAL 
RESISTANCE IN CROP PLANTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This patent application claims priority under 35 U.S.C. § 
119 to US. Provisional Application Ser. No. 60/682,814, 
?led May 20, 2005, the disclosure of Which is incorporated 
herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
The invention Was supported by Grant 5-41170 from the 
Kentucky Tobacco Research And Development Center, and 
therefore the government may have rights in the invention. 
TECHNICAL FIELD 
Methods of producing and using compositions useful as 
antimicrobial agents are provided. More particularly, these 
compositions involve the use of phylloplanin proteins. 
BACKGROUND 
The need for discovery of neW anti-fungal and anti-bacte 
rial agents for use in preventing human and animal disease is 
growing because resistance to existing antibiotics is increas 
ing. In agriculture, available approaches for preventing crop 
loss due to particularly fungal diseases are inadequate in 
many cases. Oomycete fungi are signi?cant causes of disease 
in many plant crops, including tobacco, and it is important 
that We explore alternate approaches to microbial disease 
control in plants effected by these fungi. In 1979, an epidemic 
of blue mold (caused by the oomycete Peronospora Zabacina) 
caused an estimated “.5 1.1 billion loss of tobacco crops in 
Ontario. In the future, outbreaks such as this may be just as 
damaging to tobacco groWn for molecular farming purposes 
as for conventional tobacco production. 
SUMMARY 
The invention relates to an isolated nucleic acid molecule 
comprising the polynucleotide sequence set forth in SEQ ID 
NO: 17 or a homolog thereof With >80% identity. The inven 
tion further relates to a polypeptide encoded by the poly 
nucleotide sequence of SEQ ID NO: 17 or a homolog thereof 
With >80% identity, such as SEQ ID NO:18 Which is a dis 
ease- or pest-resistance conferring protein, more speci?cally 
a phylloplanin protein. The invention further relates to a 
method of inhibiting microbial proliferation in or on a plant 
comprising overexpres sion of phylloplanin genes in the plant, 
or contacting an infected plant With a phylloplanin protein. 
The invention further provides a novel promoter sequence 
that is useful for expression of a protein of interest. In accor 
dance With the invention, a nucleic acid construct is provided 
comprising a non-coding regulatory domain isolated 
upstream from a Phylloplanin gene, Wherein said non-coding 
regulatory domain is operably associated With a nucleic acid 
Which expresses a protein of interest, Wherein said nucleic 
acid is heterologous to said non-coding domain, and Wherein 
the non-coding regulatory domain comprises a sequence at 
least 80% identical to the sequence set forth in SEQ ID 
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2 
NOz34. The construct comprises a transcriptional and trans 
lational initiation region and translational termination region 
functional in plants. 
The invention further relates to plants selected from the 
group consisting of corn, soybean, tobacco, potato, tomato, 
pepper, datura, alfalfa, cucumber, and medicago, genetically 
modi?ed by a polynucleotide of the invention. 
The invention further relates to a method of inhibiting 
microbial proliferation in an organism comprising adminis 
tering a therapeutically effective amount of a phylloplanin 
polypeptide. 
The invention further relates to a method of screening 
endogenous proteins having antimicrobial properties on a 
plant leaf surface comprising a) Washing the plant leaf surface 
With an aqueous solution; b) collecting the aqueous solution 
after Washing; and c) analyZing the solution for proteins hav 
ing antimicrobial properties. 
The invention further relates to methods of screening 
endogenous proteins from plants obtained from a plant of a 
species selected from the group consisting of Medicago sp., 
Trifolium sp., Ulmus sp., Pyrus malus, Prunus armeniaca, 
Cynara acolymus, Asparagus o?icinale, Hordeum sp., 
Galium sp., Bela vulgaris, Prunus serolina, I/igna sinensis, 
Nyssa sylvalica, Quercus sp., Arlocarpus allilis, Brassica sp., 
Andropogon scoparius, Fagopyrum sagillalum, Manihol 
esculenza, Apium graveolens, Agrapyron deserzarum, Carnus 
?orida, Phaseolus sp., Trilicum sp., Oenolhera caespilosa, 
Carya sp., Lacluca sp., Impatiens sp., Helianlhus sp., Ledum 
decumbens, Aslragaluspallersoni, Selaria ilalica, Vaccinium 
mylrillus, Avena saliva, Pelroselinum crispum, Paslinaca 
saliva, Pisum sp., Prunus sp., Pyrus communis, Musa para 
disiaca, Aslragaluspreussii, Raphanus salivus, Secalse cere 
ale, Sassa?’as albidum, Alriplex conferlifolia, Zillandsia 
usneoides, Spinacia oleracea, Liquidambar slyraci?ua, 
Linaria Zriphylla, Liriodendron Zulipfera, I/icia sp., CiZrullus 
vulgaris, Melilolus sp., Salix sp., Rhus copallina, Nicoliana 
sp., I/iZis sp., Dalura sp., Medicago sp., Lycopersicon sp., 
Solanum sp., Capsicum sp., Cucumis sp., Fragaria sp., Petu 
nia sp., Geranium sp., Coleus sp., Slevia sp., Oryza sp., 
Nepela sp., Zea mays, Glycine max. 
The invention provides phylloplanin proteins, methods and 
compositions, as an avenue for enhancing fungal resistance in 
plants, using tobacco and blue mold as the model. In addition, 
the invention demonstrates that phylloplanin is an antimicro 
bial protein useful in molecular farming products. Plant phyl 
loplanins have the potential to be used as antibiotics against 
human and animal microorganisms. Overexpression of phyl 
loplanin genes in crop plants such as corn, soybean, tobacco, 
tomato, potato, pepper, datura, alfalfa, cucumber, medicago 
and the like enhances crop resistance to fungal and bacterial 
microorganisms. In addition, phylloplanins can be used as a 
topical fungicide. 
Other aspects of the invention are described throughout the 
speci?cation. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-C depicts data demonstrating proteins present 
on plant leaf surfaces. A: 40>< magni?cation of TI 1068 phyl 
loplane With tall glandular secreting trichomes (TGSTs) and 
US 7,528,232 B2 
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short glandular trichome (SGTs) identi?ed. B: Coomassie 
stained SDS-PAGE of TI 1068-derived samples. Phyl 
loplanins I-IV are identi?ed. Loaded volumes of LWW (B,d) 
and sterile-groWn plant LWW (B,e) represent 25 cm2 leaf 
surface area. MWt (B,a) denotes protein standards. C: Silver 
stained SDS-PAGE of LWWs from ?eld-groWn TI 1068 (C,b; 
10 cm2), G. max (C,c; 30 cm2), andH. annuus (C,d; 6 cm2). 
MWt (C,a) denotes protein standards. 
FIGS. 2A-B depicts proteins in TI 1068 LWW that inhibit 
R Zabacina spore germination and leaf infection. A: R Zaba 
cina spore germination assays (Pt), Coomassie-stained SDS 
PAGE (sds), and Western blots With 1:10,000 phylloplanin 
antiserum (W). a, Water+spores. b, TI 1068 LWW (diluted to 
100 ng/uL total protein)+spores. c, TI 1068 LWW (100 ng/uL 
total protein) digested With Proteinase K (ProtK)+spores. 
ArroW marks residual, soluble ProtK. B: P Zabacina leaf 
infection assay of Petite Havana. a, Water+spores (104 spores/ 
mL). A sporulating lesion is indicated With arroW. b, TI 1068 
LWW (diluted to 50 ng/uL)+spores (104 spores/mL). 
FIG. 3 provides a nucleotide (SEQ ID NO: 17) and pre 
dicted amino acid sequence (SEQ ID NO:18) of TI 1068 
Phylloplanin. Nucleotides are numbered on right. Start and 
stop codons are underlined, and the signal sequence is bold 
faced. Segments corresponding to peptides amino acid-N1, 
amino acid-T1, amino acid-T2, amino acid-T3, amino acid 
T4, and amino acid-P1 are marked by lines above the amino 
acid sequence and labelled. 
FIGS. 4A-D depicts E. cob-expressed TI 1068 phyllopla 
nin inhibits R Zabacina spore germination. Coomassie 
stained SDS-PAGE (sds), Western blots With 1:10,000 phyl 
loplanin antiserum (W), and P Zabacina spore germination 
assays (Pt). a: E. coli expressed MBP-PhyllP (M-P; 160 
ng/uL total protein) treated With Factor-Xa. ArroW indicates 
released PhyllP. b: E. coli expressed MBP-PhyllP (160 ng/uL 
total protein) treated With Factor-Xa and Proteinase-K 
(ProtK). Volume used Was equivalent to (a). c: E. coli 
expressed MBP (M; 200 ng/uL total protein treated With 
Factor-Xa. d: E. coli expressed MBP (200 ng/uL, total pro 
tein) treated With Factor-Xa and ProtK Volume used Was 
equivalent to (c). 
FIGS. 5A-C shoWs that the phylloplanin promoter directs 
protein expression in short glandular trichomes (SGTs). A: 
Magni?cation of X-gluc stained plantlet leaf from TI 1068 
With GUS under control of phylloplanin promoter. Tall glan 
dular secreting trichomes (TSGTs) are also indicated. B: 
X-gluc stained SGT on TI 1068 plantlet expressing GUS 
under control of phylloplanin promoter. Surface structures 
are indicated. C: Fluorescent magni?cation/detection of TI 
1068 plantlet With GFP under control of phylloplanin pro 
moter. GFP Was present only in SGT gland cells. The yelloW 
arroWs indicate constrictions betWeen gland cells that may be 
“pores” to release protein to the leaf surface. 
FIG. 6 depicts groWth curves of E. coli BL21 cultures 
expressing N. Zabacum PR-5a and A. Zhaliana AAP75801 
With the pET-30 system. Induction With IPTG, if performed, 
occurred at 2.25 hrs. The IPTG-induced PR-5a expressing 
culture continued logarithmic groWth along With control 
BL21 cells and non-IPTG-induced cultures. The IPTG-in 
ducedAAP75801 expressing culture seemed to stop groWing. 
This suggests that the induced AAP75801 protein product 
Was toxic toWards the culture. 
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FIG. 7 depicts inhibition of R Zabacina Spore Germination 
and Leaf Infection by T-Phylloplanins in LWW. For both 
assays, the results of a single experiment that is representative 
of three separate experiments are shoWn. Open circles, spore 
germination; closed squares, leaf infection. 
FIGS. 8A-B depicts multiple alignment and phylogenetic 
analysis of T-phylloplanin and similar sequences in other 
plants (SEQ ID NOs: 18 and 36-48, respectively). A: The 
amino acid sequence of T-phylloplanin Was aligned against 
sequences giving signi?cant BLAST similarity scores using 
the ClustalW algorithm of DNASTAR (Lasergene SoftWare, 
Madison, Wis.). Amino acids conserved betWeen any six 
sequences are indicated in reverse contrast. B: Unrooted phy 
logenetic tree shoWing the evolutionary relationships 
betWeen the sequences in (A). Bootstrap values of >50% are 
given on the respective branches. The ?rst tWo letters of the 
acronyms indicate the species (Am, Anlirrhinum majus; At, 
Arabidopsis Zhaliana; Br, Brassica rapa; Gm, Glycine max; 
Ha, Helianlhus annuus; Le, Lycopersicon eschulenlum; Nt, 
Nicoliana Zabacum; Os, Oryza saliva; Pt, Populus [remu 
loides; Sr, Slevia rebaudiana; St. Slevia luberosum). The 
GenBank accession numbers of the sequences folloW the 
species identi?ers. Tissue localiZations of ESTs and cDNAs 
are indicated beneath the acronyms. 
FIG. 9 depicts the Promoter sequence of the gene Phyl 
loplanin (SEQ ID NOS:49 and 50).A putative TATA box (—33 
to —30) and a putative CAAT box (—47 to —43) are bold-faced. 
The phylloplanin transcription start site (+1) is bold-faced 
and underlined. The phylloplanin start codon (+48) is under 
lined. A portion of the phylloplanin amino acid sequence is 
indicated. 
DETAILED DESCRIPTION 
The invention is directed to methods and compositions 
useful as antimicrobial and antifungal agents. More particu 
larly, these methods and compositions involve the use of 
phylloplanin proteins as antimicrobial and antifungal agents 
in plants, humans and animals. 
DEFINITIONS 
To facilitate understanding of the invention set forth in the 
disclosure that folloWs, a number of terms are de?ned beloW. 
The term “innate immunity” refers to a defense system that 
inhibits groWth of microorganisms at their ?rst point of con 
tact. 
The term “phylloplane” refers to a plant’s epidermal layer 
that contributes to the innate pest/disease resistance of the 
plant. 
The term “phylloplanins” refers to proteins produced by a 
plant’s epidermal layer that contribute to the innate pest/ 
disease resistance of the plant. 
The term “TGSTs” refers to the tall glandular secreting 
trichome. 
The term “SGTs” refers to the short glandular trichome. 
The meaning of other terminology used herein should be 
easily understood by someone of ordinary skill in the art. 
Fungicides are commonly used to inhibit fungal disease in 
plants, and are commercially available and used for prevent 
ing crop loss. Examples of such fungicides are listed in the 
folloWing table. 
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CHEMICAL COMMON 
FRAC CODEl TARGET SITE2 GROUP NAME3 GROUP4 NAME5 COMMENTS6 
I mitosis: MBC — benZimidaZoles FuberidaZole Resistance 
[5-tubuline ?ingicides benomyl thiabendaZole common in many 
assembly (Methyl carbendaZim fungal species. 
BenZimidaZole thiophanates thiophanate Several target site 
Carbamates) thiophanate-methyl mutations, mostly 
E198NG/K, FZOOY 
Positive cross 
resistance 
betWeen the group 
members. 
Negative cross 
resistance to N 
Phenylcarbamates 
High risk. See 
FRAC 
BenZimidaZole 
Guidelines for 
resistance 
management. 
2 NADH cytochrome dicarboXimides chloZolinate Resistance 
c reductase in lipid iprodione common in Bolryris 
peroXidation procymidone cinerea and found 
(proposed) vincloZolin in some other 
fungal species. 
S everal mutations 
found in OSI 
histidine kinase 
(Daf I), mostly 
I3 65 S Cross 
resistance 
common betWeen 
the group 
members. Medium 
to high risk. See 
FRAC 
Dicarboximide 
Guidelines for 
resistance 
management. 
3 C14- DMI-fungicides imidaZoles imaZalil There are great 
demethylation (DeMethylation pefuraZoate differences in the 
in sterol Inhibitors) prochloraZ activity spectra of 
biosynthesis (SBI: Class I) tri?umizole the different DMI 
piperaZines triforine fungicides. 
pyridines pyrifenoX Resistance is 
pyrimidines fenarimol knoWn in various 
nuarimol fungal species. 
triazoles aZaconaZole Several resistance 
bitertanol mechanisms 
bromuconaZole knoWn incl. target 
cyproconaZole site mutation 
difenoconaZole Y13 6F, ABC 
diniconaZole transporters and 
epoXiconaZole others. Generally 
fenbuconaZole Wise to accept that 
?uquinconazole cross resistance is 
?usilaZole present betWeen 
flutriafol fungicides active 
heXaconaZole against the same 
imibenconaZole fungus. DMI 
ipconaZole fungicides are 
metconaZole Sterol Biosynthesis 
myclobutanil Inhibitors (SBI’s) 
penconaZole but shoW no cross 
propiconaZole resistance to other 
prothioconaZole SBI classes. 
simeconaZole Medium risk. See 
tebuconaZole FRAC SBI 
tetraconaZole Guidelines for 
triadimefon resistance 
triadimenol management. 
triticonaZole 
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CHEMICAL COMMON 
FRAC CODEl TARGET SITE2 GROUP NAME3 GROUP4 NAMES COMMENTS6 
4 RNA polymerase I PA — fungicides acylalanines benalaxyl Resistance and 
(PhenylAmides) ?lralaxyl cross resistance 
metalaXyl well known in 
metalaxyl-M various Oomycetes 
(=mefenoxam) but mechanism 
oXaZolidinones oXadiXyl unknown. High 
butyrolactones ofurace risk. See FRAC 
Phenylamide 
Guidelines 
5 A14—reductase Amines morpholines Aldimorph Decreased 
and (“Morpholines”) dodemorph sensitivity 
A8—>A7 (SBI: Class H) fenpropimorph described for 
isomerase tridemorph powdery mildews. 
in sterol piperidines fenpropidin Cross resistance 
biosynthesis piperalin within the group 
spiroketalamines spiroxamine generally found but 
not to other SBI 
classes. Low to 
medium risk. See 
FRAC SBI 
Guidelines for 
resistance 
management. 
6 phospholipid phosphorothiolates edifenphos Resistance known 
biosynthesis, iprobenfos (IBP) for speci?c fungi. 
methyltransferase pyraZophos Low to medium 
dithiolanes isoprothiolane risk. Resistance 
management 
required if used for 
risky pathogens. 
7 complex 11 in carboxamides benodanil boscalid Resistance known 
fungal respiration carboxin for speci?c fungi. 
(succinate- fen?lram Target site 
dehydrogenase) flutolanil mutation H257L. 
?lrametpyr Medium risk. 
mepronil Resistance 
oXycarboXin management 
thi?uzamide required if used for 
risky pathogens. 
8 adenosin- hydroxy- bupirimate Medium risk. 
deaminase (2—amino—) dimethirimol Resistance and 
pyrimidines thirimol cross resistance 
known in powdery 
mildews. 
Resistance 
management 
required. 
9 methionine AP — fungicides cyprodinil Resistance known 
biosynthesis (Anilino- mepanipyrim in Bolryris and 
(proposed) Pyrimidines) pyrimethanil sporadically in 
Venturia, 
mechanism 
speculative (CGS). 
Medium risk. See 
FRAC 
Anilinopyrimidine 
Guidelines for 
resistance 
management. 
10 mitosis: N-phenyl diethofencarb Resistance known. 
[5-tubulin carbamates Target site 
assembly mutation E198K. 
Negative cross 
resistance to 
benZimidaZoles. 
High risk. 
Resistance 
management 
required. 
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CHEMICAL COMMON 
FRAC CODEl TARGET SITE2 GROUP NAME3 GROUP4 NAME5 COMMENTS6 
11 complex III of Qol-fungicides methoxy-acrylates AZoxystrobin Resistance known 
fungal respiration: (Quinone outside picoxystrobin in various ?lngal 
ubiquinol oxidase, Inhibitors) Methoxy- Pyraclostrobin species. Target 
Qo site carbamates site mutations 
Oximino acetates Kresoxim-methyl G143A, F129L and 
trifloxystrobin additional 
Oximino- metominostrobin mechanisms. 
acetamides Cross resistance 
OxaZolidine- Famoxadone shoWn betWeen all 
diones members of the 
dihydro-dioxazines fluoxastrobin Qol group. High 
imidaZolinones fenamidone risk. See FRAC 
Qol Guidelines for 
resistance 
management. 
12 MAP protein PP-?lngicides fenpiclonil Resistance found 
kinase in osmotic (PhenylPyrroles) fludioxonil sporadically, 
signal mechanism 
transduction speculative (OS-2 
kinase). LoW to 
medium risk. 
Resistance 
management 
required. 
13 G-proteins in early quinolines quinoxyfen Resistance knoWn. 
cell signalling Medium risk. 
(proposed) Resistance 
management 
required. 
14 lipid peroxidation AH-fungicides biphenyl Resistance knoWn 
(proposed) (Aromatic chloroneb to some fungi. LoW 
Hydrocarbons) dicloran to medium risk. 
(chlorophenyls, quintoZene (PCNB) Cross resistance 
nitroanilines) tecnaZene (TCNB) patterns complex 
tolclofos-methyl due to different 
heteroaromatics 1,2,4-thiadiazoles etridiaZole activity spectra. 
15 cell Wall synthesis cinnamic acids dimethomorph LoW to medium 
(proposed) risk. Resistance 
management 
required. 
16.1 reductase in MBI-R isobenZofuranone ?;halide Resistance not 
melanin (Melanin pyrroloquinolinone pyroquilon knoWn 
biosynthesis Biosynthesis triaZolobenZo- tricyclaZole 
Inhibitors — thiaZole 
Reductase 
16.2 dehydratase in MBI-D cyclopropane- carpropamid Resistance knoWn. 
melanin (Melanin carboxamide Medium risk. 
biosynthesis Biosynthesis carboxamide diclocyme Resistance 
Inhibitors — propionamide fenoxani management 
Dehydratase required. 
17 3-keto reductase hydroxyanilides fenhexamid LoW to medium 
during C4 (SBI: Class III) risk. Resistance 
demethylation in management 
sterol biosynthesis required. 
18 squalene (SBI: class IV) thiocarbamates pyributicarb Resistance not 
epoxidase in allylamines nafti?ne knoWn. Herbicide 
sterol biosynthesis terbina?ne and ?lngicide. 
Medical fungicides 
19 chitin synthase polyoxins peptidyl pyrimidine polyoxin Resistance knoWn. 
nucleoside Medium risk. 
Resistance 
management 
required. 
20 cell division phenylureas pencycuron Resistance not 
(proposed) knoWn 
21 complex III of QiI — ?lngicides cyanoimidaZole cyaZofamid Resistance risk 
fungal respiration: 
ub iquinone 
reductase, Qi site 
(Quinone inside 
Inhibitors) 
unknoWn but 
assumed to be 
medium to high 
(mutations at target 
site knoWn in 
model organisms). 
Resistance 
management 
required. 
US 7,528,232 B2 
11 12 
-continued 
CHEMICAL COMMON 
FRAC CODEl TARGET SITE2 GROUP NAME3 GROUP4 NAME5 COMMENTS6 
22 mitosis benZamides ZoXamide LoW to medium 
[5-tubulin risk. Resistance 
assembly management 
required. 
23 protein synthesis enopyranuronic blasticidin-S LoW to medium 
acid antibiotic risk. Resistance 
management 
required. 
24 protein synthesis hexopyranosyl kasugamycin Medium risk. 
antibiotic Resistance knoWn. 
Resistance 
management 
required. 
25 protein synthesis glucopyranosyl streptomycin Bactericide. 
antibiotic Resistance knoWn. 
High risk. 
Resistance 
management 
required. 
26 trehalase and/or glucopyranosyl validamycin Resistance not 
inositol- antibiotic knoWn 
biosynthesis 
27 unknoWn cyanoacetamide- cymoXanil Resistance claims 
oXimes described. LoW to 
medium risk. 
Resistance 
management 
required. 
28 cell membrane carbamates iodocarb LoW to medium 
permeability, fatty propamocarb risk. Resistance 
acids (proposed) prothiocarb management 
required. 
29 uncoupler of dinitrophenyl binapacryl Resistance not 
oXidative crotonates dinocap knoWn 
phosphorylation pyrimidinone- ferimZone Resistance not 
hydraZones knoWn 
2,6-dinitro- fluazinam LoW risk. 
anilines HoWever, resistant 
isolates ofBolryris 
claimed to exist in 
Japan in 2000 
30 inhibitors of organo tin tri phenyl tin fentin acetate Some resistance 
oXidative compounds compounds fentin chloride cases knoWn. LoW 
phospho-rylation, fentin hydroxide to medium risk 
ATP synthases 
31 DNA carboXylic acids oXolinic acid Bactericide. 
topoisomerase Resistance knoWn. 
type II (gyrase) Risk unknoWn. 
Resistance 
management 
required. 
32 DNNRNA heteroaromatics isoXaZoles hymeXaZole Resistance not 
synthesis isothiaZolones octhilinone knoWn 
(proposed) 
33 unknoWn phosphonates ethyl phosphonates fosetyl-Al Miscellanous 
phophorous acid compounds, mode 
34 unknoWn phthalamic acids tecloithalam of action generally 
(Bactericide) not knoWn. 
35 unknoWn benZotriaZines triaZoXide Use over several 
36 unknoWn benZene- ?usulfamide years has not 
sulfonamides revealed major 
37 unknoWn pyridaZinones diclomeZine resistance 
problems. 
Risk assumed to 
be loW. No cross 
resistance betWeen 
group members 
P host plant P1 benZo-thiadiaZole acibenZolar-S- Resistance not 
defence salicylic acid BTH methyl knoWn 
induction pathWay 
P2 benZisothiaZole probenaZole (also 
antibacterial and 
antifungal activity) 
13 
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U cell Wall U1 amino acid amide benthiavalicarb Mode of action and 
synthesis carbamates iprovalicarb resistance risk 
(proposed) unknown. 
ATP production in U2 thiophene- silthiofam No long term 
respiration carboxamides experience 
(proposed) available. 
complex I of U3 pyrimidinamines Di?umetorim Resistance 
respiration management 
(proposed) required if high risk 
unknoWn U4 thiocarbamate methasulfocarb organisms are 
UnknoWn U5 thiaZole- ethaboxam targeted. 
carboxamides No cross 
resistance betWeen 
group members 
M multi-site M1 inorganics Copper (different Generally 
contact activity salts) considered a lOW 
Sulphur risk group With no 
M2 dithio-carbamates ferbam signs of resistance 
and relatives mancoZeb developing to the 
maneb majority of 
metiram fungicides. No 
propineb cross resistance 
thiram betWeen Group 
Zineb members. 
Ziram 
M3 phthalimides captan 
captafol 
folpet 
M4 chloronitriles chlorothalonil 
(phthalonitriles) 
M5 sulphamides dichlo?uanid 
tolyl?uanid 
M6 guanidines dodine 
guaZatine 
iminoctadine 
M7 triazines anilaZine 
M8 quinones dithianon 
(anthraquinones) 
M9 inorganics Copper (different 
salts) 
Sulphur 
Source: WWW. frac.info/publications/ fracilist01 
lFRAC Code. Numbers and letters are used to distinguish the ?mgicide groups. The numbers Were assigned primarily according 
to the time of product introduction to the market. The letters refer to P = host plant defence inducers, M = multi-site inhibitors, 
and U = recent molecules With unknoWn mode of action. 
2Target Site of Action. If available the biochemical mode of action is given. In many cases the precise target site is not knoWn. 
HoWever, a grouping can be made due to cross resistance pro?les Within a group or in relation to other groups. 
3Group Name. The Group Names listed are Widely accepted in literature. They are based on different sources (mode of action, 
?rst important representative, chemical group). 
4Chemical Group. Sub-grouping due to chemical considerations. 
5Common name. Accepted (or proposed) common name for an individual active ingredient expected to appear on the product 
label as de?nition of the product. 
6Comments on Resistance. If ?eld resistance is knoWn to one member of the Group, it is most likely but not exclusively valid that 
cross resistance to other Group members Will be present. There is increasing evidence that cross resistance may not be clearly 
visible betWeen Group members and that the degree of the effect can differ both betWeen group members and fungal species or 
even Within species. The intrinsic risk for resistance evolution to a given fungicide group is estimated to be loW, medium or high 
according to the principles described in FRAC Monographs I and 2. A similar classi?cation list of fungicides Was published 
recently also by T. Locke on behalfofFRAC — UK (Fungicide Resistance, August 2001) and by P. Leroux (Classi?cation des fon 
gicides agricoles et resistance, Phytoma, La Defense des Vegetaux, No. 554, 43-51, November 2002). 
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Phylloplanins 
Phylloplanin polypeptides are expressed in crop plants 
such as corn, soybean, tobacco, tomato, potato, pepper, 
datura, alfalfa, cucumber, medicago, and the like. Typical 
biological activities or functions associated With this family 
of polypeptides include inhibition of fungal spore germina 
tion. In one aspect, phylloplanin polypeptides of the invention 
further include oligomers or fusion polypeptides comprising 
at least one domain portion of one or more phylloplanin 
polypeptides, and fragments of any of these polypeptides that 
are capable of inhibiting fungal germination or Which have 
antimicrobial activity. 
This invention provides a family of polypeptides, termed 
phylloplanins, and the utility of these polypeptides and 
homologous polypeptides (>80% homology, commonly 
>90% homology, more typically >95% homology) from other 
species as antimicrobials (e.g., antifungals and antibacterials) 
against human and animal pathogens. A phylloplanin of the 
invention Was ?rst identi?ed by Washing Nicoliana Zabacum 
leaves With Water, lyophiliZing the Wash solution, resuspend 
ing the lyophiliZed material in Water to give a leaf Water Wash 
(LWW) sample, and analyZing LWW by SDS-PAGE (FIG. 
1). 
A phylloplanin polypeptide of the invention includes a 
polypeptide that shares a su?icient degree of amino acid 
identity or similarity to a polypeptide having a sequence as set 
forth in SEQ ID NO: 18, to be identi?ed by those of skill in the 
art as a polypeptide likely to share particular structural 
domains, have biological activities in common With phyl 
loplanin polypeptides, and/or bind to antibodies that also 
speci?cally bind to phylloplanins. The phylloplanin polypep 
tides of the invention may be isolated from naturally occur 
ring sources. Alternatively, the phylloplanin polypeptides 
may be recombinantly produced and have the same structure 
as naturally occurring phylloplanin polypeptides, or may be 
produced to have structures that differ from naturally occur 
ring phylloplanin polypeptides. Polypeptides derived from 
any phylloplanin polypeptide of the invention by any type of 
alteration (for example, but not limited to, insertions, dele 
tions, or substitutions of amino acids, changes in glycosyla 
tion of the polypeptide, refolding or isomeriZation to change 
its three-dimensional structure or self-association state, and 
changes to its association With other polypeptides or mol 
ecules) are also phylloplanin polypeptides for the purposes of 
the invention. Therefore, the polypeptides provided by the 
invention include polypeptides characterized by amino acid 
sequences similar to those of the phylloplaninpolypeptides or 
similar to phylloplanin polypeptides described herein, but 
into Which modi?cations are naturally provided or deliber 
ately engineered. A polypeptide that shares biological activi 
ties in common With members of the phylloplanin polypep 
tide family is a polypeptide having antimicrobial activity 
(e. g., antifungal activity) 
Amino acid substitutions and other alterations (deletions, 
insertions, and the like) to the phylloplanin amino acid 
sequences (e.g., SEQ ID NOzl8) are predicted to be more 
likely to alter or disrupt phylloplanin polypeptide activities if 
they result in changes to the consensus residues of the amino 
acid sequences, see FIGS. 8A and B, and particularly if those 
changes do not substitute an amino acid of similar structure 
(e. g., such as substitution of any one of the aliphatic residues 
-Ala, Gly, Leu, He, or Val- for another aliphatic residue), or a 
residue present in other phylloplanin polypeptides at that 
conserved position. Conversely, if a change is made to a 
phylloplanin polypeptide resulting in substitution of a residue 
at a position in the alignment that is not conserved from one 
of the other phylloplanin and phylloplanin-like sequences, it 
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is less likely that such an alteration Will affect the function of 
the altered phylloplanin polypeptide. The invention provides 
phylloplanin polypeptides and fragments of phylloplanin 
polypeptides, comprising altered amino acid sequences. 
Altered phylloplanin polypeptide sequences share at least 
75% to 80%, or typically at least 85% to 90%, or more 
commonly at least 95% to 97.5%, or most commonly at least 
99%, or most commonly at least 99.5% amino acid identity 
With the phylloplanin amino acid sequences provided herein. 
The invention provides both full-length and mature forms 
of phylloplanin polypeptides. “Full-length” polypeptides are 
those having the complete primary amino acid sequence of 
the polypeptide as initially translated (see e.g., SEQ ID 
NOzl7 and 18). The amino acid sequences of full-length 
polypeptides can be obtained, for example, by translation of 
the complete open reading frame (“ORF”) of a cDNA mol 
ecule (e.g., SEQ ID NO: 17). Several full-length polypeptides 
may be encoded by a single genetic locus if multiple mRNA 
forms are produced from that locus by alternative splicing or 
by the use of multiple translation initiation sites. An example 
of a full length polypeptide of the invention includes the 
sequence as set forth in SEQ ID NO: 1 8, from amino acid 1 to 
amino acid 150. The “mature form” of a polypeptide refers to 
a polypeptide that has undergone post-translational process 
ing steps such as cleavage of the signal sequence or pro 
teolytic cleavage to remove a prodomain. Multiple mature 
forms of a particular full-length polypeptide may be pro 
duced, for example by cleavage of the signal sequence at 
multiple sites, or by differential regulation of proteases that 
cleave the polypeptide. The mature form(s) of such polypep 
tide may be obtained by expression, in a suitable plant cell or 
other host cell, of a polynucleotide that encodes the full 
length polypeptide. The sequence of the mature form of the 
polypeptide may also be determinable from the amino acid 
sequence of the full-length form, through identi?cation of 
signal sequences or protease cleavage sites. An example of a 
mature form of the polypeptide of the invention is SEQ ID 
NO: 18, from amino acid residue xl to amino acid residue 
150, Wherein x1 is an amino acid betWeen and including 
residues 22, 23 and 24 (e.g., amino acid 24-150 of SEQ ID 
NO: 18). The phylloplanin polypeptides of the invention also 
include those that result from post-transcriptional or post 
translational processing events such as alternate mRNA pro 
cessing Which can yield a truncated but biologically active 
polypeptide. Also encompassed Within the invention are 
variations attributable to proteolysis such as differences in the 
N- or C-termini upon expression in different types of host 
cells, due to proteolytic removal of one or more terminal 
amino acids from the polypeptide (generally from about 1 to 
5 terminal amino acids). 
The invention further includes phylloplanin polypeptides 
With or Without associated native-pattem glycosylation. 
Polypeptides expressed in yeast or plant expression systems 
(e.g., COS-l or CHO cells) can be similar to or signi?cantly 
different from a native polypeptide in molecular Weight and 
glycosylation pattern, depending upon the choice of expres 
sion system. Expression of polypeptides of the invention in 
bacterial expression systems, such as E. coli, typically pro 
vides non-glycosylated molecules. Further, a given prepara 
tion can include multiple differentially glycosylated species 
of the polypeptide. Glycosyl groups can be removed through 
conventional methods, in particular those utiliZing glycopep 
tidase (Boehringer Mannheim). 
Species homologues of phylloplanin polypeptides and 
polynucleotides are also provided by the invention. As used 
herein, a “species homologue” is a polypeptide or polynucle 
otide With a different species of origin from that of a given 



























